Last reviewed · How we verify
Kyprolis (carfilzomib)
Kyprolis (generic name: carfilzomib) is a Proteasome Inhibitor [EPC] drug developed by Amgen. It is currently FDA-approved (first approved 2012) for Multiple myeloma, Relapse multiple myeloma.
Kyprolis works by blocking the proteasome, a complex that breaks down proteins in cells.
Kyprolis is a medication used to treat multiple myeloma in relapse, recurrent, refractory, and relapsed cases. It works as a 26S proteasome inhibitor, a type of protein that targets and blocks the 26S proteasome.
At a glance
| Generic name | carfilzomib |
|---|---|
| Sponsor | Amgen |
| Drug class | Proteasome Inhibitor [EPC] |
| Target | Proteasome subunit beta type-5 |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 2012 |
| Annual revenue | 1300 |
Mechanism of action
Carfilzomib is tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds to the N-terminal threonine-containing active sites of the 20S proteasome, the proteolytic core particle within the 26S proteasome. Carfilzomib had antiproliferative and proapoptotic activities in vitro in solid and hematologic tumor cells. In animals, carfilzomib inhibited proteasome activity in blood and tissue and delayed tumor growth in models of multiple myeloma, hematologic, and solid tumors.
Approved indications
- Multiple myeloma
- Relapse multiple myeloma
Common side effects
- Anemia
- Diarrhea
- Fatigue
- Pneumonia
- Cough
- Dyspnea
- Upper respiratory tract infection
- Thrombocytopenia
- Edema peripheral
- Hypertension
- Pyrexia
- Nausea
Drug interactions
- P-glycoprotein Substrates
Key clinical trials
- Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients (PHASE3)
- Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma (PHASE1,PHASE2)
- Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma (PHASE3)
- Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma (PHASE3)
- Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma (PHASE2)
- Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma (PHASE2)
- CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma (PHASE1)
- A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Kyprolis CI brief — competitive landscape report
- Kyprolis updates RSS · CI watch RSS
- Amgen portfolio CI
Frequently asked questions about Kyprolis
What is Kyprolis?
How does Kyprolis work?
What is Kyprolis used for?
Who makes Kyprolis?
What is the generic name of Kyprolis?
What drug class is Kyprolis in?
When was Kyprolis approved?
What development phase is Kyprolis in?
What are the side effects of Kyprolis?
What is Kyprolis's annual revenue?
What does Kyprolis target?
Related
- Drug class: All Proteasome Inhibitor [EPC] drugs
- Target: All drugs targeting Proteasome subunit beta type-5
- Manufacturer: Amgen — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Multiple myeloma
- Indication: Drugs for Relapse multiple myeloma
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing